Concerns on Diagnosis and Treatment of Breast Cancer in China.
Wang Shen-Ming
DOI: https://doi.org/10.1097/00029330-200710020-00002
2007-01-01
Abstract:Breast cancer is one of the neoplasms that have greatest negative psychological impact on the sufferers. Although China is among the low morbidity country of breast cancer, its yearly increasing rate in China is 1%-2% higher than the average rate of the world.1 Due to its largest population in the world, China tops the world in its breast cancer cases but general medical care for the patients still lags behind the developed countries. These issues are related to the diagnosis and treatment of breast cancer in China. Although administration of tamoxifen (TAM) and aromatase inhibitor in the high-risk population can reduce the morbidity of breast cancer,2 no effective first-line strategy is available for prevention of breast cancer. Early diagnosis, therefore, plays a key role in the management of breast cancer. Statistical data on 135 000 cases of breast cancer from the American Cancer Society show that white Americans with breast carcinoma 2-3 cm in diameter had a 5-year death rate of 25%, whereas those with the tumor ≤ 0.5 cm in diameter had a 20-year survival rate of 97%, indicating the significance of early diagnosis.3 X-ray mammography is the most effective way for breast cancer screening, which contributes to the diagnosis of 50% of patients with impalpable breast cancer and 70% of patients with breast cancer in situ. As reported, patients aged 40 to 49 years were diagnosed 1.7 years earlier and those aged above 50 years were diagnosed 3 years earlier on average with this technique than controls.1 It is recommended in western countries that women aged above 40 years receive mammography once a year. Because the peak age for occurrence of breast cancer is earlier in China than in the western countries, the recommended age for breast cancer screening in China should be earlier than that in the western countries. However, the specific age for screening and the carcinogenicity of X-ray screening have to be studied in China. Additionally, most patients with breast cancer in the western countries are postmenopausal women, whose breast cancer can be easily found because the predominant part in breast are adipose tissue, while the peak occurrence of breast cancer in China is seen in 45-year-old women, whose carcinoma may be missed by radiography owing to the predominantly glandular breast at this age. Therefore, early diagnosis of breast cancer in China should be a combination of different ways. Ultrasonography can be repeated without pain and invasiveness as a tool for screening or a definite diagnosis of lesions suspected on breast X-ray radiography or physical examination. Magnetic resonance imaging (MRI) is highly sensitive and specific for breast cancer as compared with X-ray, but it is not proper for mass screening because of high cost, time-consuming and use of contrast medium. The imaging-guided micro-invasive biopsy is the golden standard for the diagnosis of breast cancer and also the last procedure for early diagnosis. The currently used vacuum-assisted breast micro-invasive biopsy is characterized by significant improvement of diagnostic accuracy compared with the traditional procedures. With the development of gene techniques, gene detection has been clinically implemented in early diagnosis of breast cancer. Recently, the American Society of Clinical Oncology reported that 8 biological markers of breast cancer including carcino-embryonic antigen (CEA), carbohydrate antigen 153 (CA153), breast cancer antigen 225 (BCA225), epidermal growth factor receptor-2 (p185), soluble segment of cytokeratin 19 (Cvfra2121) etc were closely associated with breast cancer, but they has limited sensitivity and specificity or a low positive rate for early breast cancer (Stage I breast cancer).4 A study by Johns Hopkins Institute of Medicine compared the expression of the serous proteins between patients with stage 0-I breast cancer and healthy counterparts using 3 biological markers from the above 8 markers as a combination for breast cancer screening, which resulted in a sensitivity of 93% and a specificity of 91% in the diagnosis of breast cancer, indicating its great potential in the early diagnosis of breast cancer.5 Nowadays, screening and determination of ideal biological markers in peripheral blood and establishment of a convenient, rapid, and highly sensitive method are essential to improving the accuracy of early diagnosis of breast cancer. The great socioeconomic differences between urban and rural areas or between different geographical regions in China lead to different understanding of public health care knowledge and unequal distribution of public health care resources. These may partly contribute to the lower early diagnosis rate of breast cancer in this country compared to the developed countries. Therefore, health education on breast cancer, including basic knowledge, self-inspection, and mass screening are important measures for early diagnosis of breast cancer in the high-risk population. Extension of surgical excision does not play a crucial role in patients' survival since breast cancer is a systemic disease. The surgical procedures for breast cancer have undergone great changes with the primary objective for local control. Extensive radical mastectomy has been replaced by radical mastectomy limited to patients in stage III, and modified radical mastectomy with pectoral muscle saving and conservative breast operation become the routine surgical procedures. A randomized controlled trial with a follow-up for 20 years shows that the survival rate of patients in stages I and II is almost the same for patients receiving conservative breast operation (58.3%) or modified radical operation (58.8%).6 Therefore, given with comprehensive adjuvant therapy, patients in stages I and II can undergo conservative breast operation for a good physical shape and significant improvement of life quality. On the basis of the satisfying outcomes of conservative breast operation, surgeons are making efforts to preserve the axillary fossa with sentinel lymph node detection. Although there are disputes over the accuracy of sentinel node biopsy, its theoretical rationality and technical feasibility have been generally recognized. Since conservative breast operation is largely dependent on radiotherapy, patients from rural areas or small towns, especially those with financial problems, may be inaccessible to radiotherapy. Therefore, willingness and financial status should be taken into consideration while decision is made for surgery. Medication for breast cancer includes chemotherapy and endocrine therapy. Breast cancer is one of the most chemotherapy-sensitive solid carcinomas. Chemotherapy can reduce the risks of recurrence and metastasis of the tumor after operation, alleviate the severity of the disease, and prolong the survival of metastatic patients. Patients with lymph nodes positive, lymph nodes negative with mass ≥ 2 cm, estrogen receptor (ER) negative, nucleus grading of III, tumor embolus in vessels, overexpression of Her-2 and high percentage of S phase cells should receive adjuvant chemotherapy after surgery. Many clinical studies have shown that anthracycline and taxane are effective agents for breast cancer. Neoadjuvant chemotherapy provides an opportunity to observe therapeutic reactions, shrink neoplasm in size, lessen adhesion to the surrounding tissues, and make unresectable tumor operable. Patients with breast cancer of ER positive and/or PR positive, regardless of their age, menstruation and TNM staging, should receive endocrine therapy. Estrogen receptor antagonist tamoxifen (TAM), the most classic endocrinotherapy agent, can decrease the postoperative recurrence and metastasis of breast cancer, and reduce the risk of contralateral breast cancer. The 3rd generation of aromatase inhibitors, anastrozole, letrozole, and exemestane are believed to be superior to TAM in efficacy with fewer side effects. The peak age of breast cancer in Chinese women is before the period of menopause, ER/PR expression increases with age and endocrine therapy is more favorable for postmenopausal women than for premenopausal ones, the regimen of endocrine therapy and its therapeutic efficacy should therefore be further studied in China baased on the mentioned facts. There are two problems in medication for breast cancer in China: (1) improper medication, including indications, regimen, dosage and therapeutic course; and (2) few large cases prospective randomized controlled trials. The present medication is primarily based on the clinical data from western countries. Patients of different races from different countries have different reactions to the same medication. Thus we should push studies on medication and set up guideline suitable for Chinese breast cancer patients.